127 related articles for article (PubMed ID: 30005872)
1. The FGF2 aptamer inhibits the growth of FGF2-FGFR pathway driven lung cancer cells.
Hamamoto J; Yasuda H; Nonaka Y; Fujiwara M; Nakamura Y; Soejima K; Betsuyaku T
Biochem Biophys Res Commun; 2018 Sep; 503(3):1330-1334. PubMed ID: 30005872
[TBL] [Abstract][Full Text] [Related]
2. Effect of FGF/FGFR pathway blocking on lung adenocarcinoma and its cancer-associated fibroblasts.
Hegab AE; Ozaki M; Kameyama N; Gao J; Kagawa S; Yasuda H; Soejima K; Yin Y; Guzy RD; Nakamura Y; Ornitz DM; Betsuyaku T
J Pathol; 2019 Oct; 249(2):193-205. PubMed ID: 31090071
[TBL] [Abstract][Full Text] [Related]
3. A neutralizing RNA aptamer against EGFR causes selective apoptotic cell death.
Esposito CL; Passaro D; Longobardo I; Condorelli G; Marotta P; Affuso A; de Franciscis V; Cerchia L
PLoS One; 2011; 6(9):e24071. PubMed ID: 21915281
[TBL] [Abstract][Full Text] [Related]
4. Neighbors' death is required for surviving human adenocarcinoma PC-9 cells in an early stage of gefitinib treatment.
Takahashi M; Fukuoka M; Yoshioka K; Hohjoh H
Biochem Biophys Res Commun; 2016 Oct; 479(2):393-397. PubMed ID: 27659708
[TBL] [Abstract][Full Text] [Related]
5. Interaction between the estrogen receptor and fibroblast growth factor receptor pathways in non-small cell lung cancer.
Siegfried JM; Farooqui M; Rothenberger NJ; Dacic S; Stabile LP
Oncotarget; 2017 Apr; 8(15):24063-24076. PubMed ID: 28445992
[TBL] [Abstract][Full Text] [Related]
6. Activation of the FGF2-FGFR1 autocrine pathway: a novel mechanism of acquired resistance to gefitinib in NSCLC.
Terai H; Soejima K; Yasuda H; Nakayama S; Hamamoto J; Arai D; Ishioka K; Ohgino K; Ikemura S; Sato T; Yoda S; Satomi R; Naoki K; Betsuyaku T
Mol Cancer Res; 2013 Jul; 11(7):759-67. PubMed ID: 23536707
[TBL] [Abstract][Full Text] [Related]
7. Dual Therapeutic Action of a Neutralizing Anti-FGF2 Aptamer in Bone Disease and Bone Cancer Pain.
Jin L; Nonaka Y; Miyakawa S; Fujiwara M; Nakamura Y
Mol Ther; 2016 Nov; 24(11):1974-1986. PubMed ID: 27506449
[TBL] [Abstract][Full Text] [Related]
8. Aptamer targeting EGFRvIII mutant hampers its constitutive autophosphorylation and affects migration, invasion and proliferation of glioblastoma cells.
Camorani S; Crescenzi E; Colecchia D; Carpentieri A; Amoresano A; Fedele M; Chiariello M; Cerchia L
Oncotarget; 2015 Nov; 6(35):37570-87. PubMed ID: 26461476
[TBL] [Abstract][Full Text] [Related]
9. Fibroblast growth factor (FGF) and FGF receptor-mediated autocrine signaling in non-small-cell lung cancer cells.
Marek L; Ware KE; Fritzsche A; Hercule P; Helton WR; Smith JE; McDermott LA; Coldren CD; Nemenoff RA; Merrick DT; Helfrich BA; Bunn PA; Heasley LE
Mol Pharmacol; 2009 Jan; 75(1):196-207. PubMed ID: 18849352
[TBL] [Abstract][Full Text] [Related]
10. Prognostic impact of fibroblast growth factor 2 in non-small cell lung cancer: coexpression with VEGFR-3 and PDGF-B predicts poor survival.
Donnem T; Al-Shibli K; Al-Saad S; Busund LT; Bremnes RM
J Thorac Oncol; 2009 May; 4(5):578-85. PubMed ID: 19318994
[TBL] [Abstract][Full Text] [Related]
11. Molecular Basis of the Antiangiogenic Action of Rosmarinic Acid, a Natural Compound Targeting Fibroblast Growth Factor-2/FGFR Interactions.
Pagano K; Carminati L; Tomaselli S; Molinari H; Taraboletti G; Ragona L
Chembiochem; 2021 Jan; 22(1):160-169. PubMed ID: 32975328
[TBL] [Abstract][Full Text] [Related]
12. Multiple Therapeutic Applications of RBM-007, an Anti-FGF2 Aptamer.
Nakamura Y
Cells; 2021 Jun; 10(7):. PubMed ID: 34203430
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA
Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836
[TBL] [Abstract][Full Text] [Related]
14. In vitro selection of aptamer S1 against MCF-7 human breast cancer cells.
Zhang WY; Chen HL; Chen QC
Bioorg Med Chem Lett; 2019 Aug; 29(16):2393-2397. PubMed ID: 31196711
[TBL] [Abstract][Full Text] [Related]
15. The broad-spectrum anti-DNA virus agent cidofovir inhibits lung metastasis of virus-independent, FGF2-driven tumors.
Liekens S; Noppen S; Gijsbers S; Sienaert R; Ronca R; Tobia C; Presta M
Oncotarget; 2015 Mar; 6(7):4633-48. PubMed ID: 25609197
[TBL] [Abstract][Full Text] [Related]
16. Identification of a novel extracellular inhibitor of FGF2/FGFR signaling axis by combined virtual screening and NMR spectroscopy approach.
Pagano K; Listro R; Linciano P; Rossi D; Longhi E; Taraboletti G; Molinari H; Collina S; Ragona L
Bioorg Chem; 2023 Jul; 136():106529. PubMed ID: 37084585
[TBL] [Abstract][Full Text] [Related]
17. Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer.
Donev IS; Wang W; Yamada T; Li Q; Takeuchi S; Matsumoto K; Yamori T; Nishioka Y; Sone S; Yano S
Clin Cancer Res; 2011 Apr; 17(8):2260-9. PubMed ID: 21220474
[TBL] [Abstract][Full Text] [Related]
18. Targeting of suicide gene delivery in pancreatic cancer cells via FGF receptors.
Kleeff J; Fukahi K; Lopez ME; Friess H; Büchler MW; Sosnowski BA; Korc M
Cancer Gene Ther; 2002 Jun; 9(6):522-32. PubMed ID: 12032663
[TBL] [Abstract][Full Text] [Related]
19. Biological activity of substrate-bound basic fibroblast growth factor (FGF2): recruitment of FGF receptor-1 in endothelial cell adhesion contacts.
Tanghetti E; Ria R; Dell'Era P; Urbinati C; Rusnati M; Ennas MG; Presta M
Oncogene; 2002 May; 21(24):3889-97. PubMed ID: 12032827
[TBL] [Abstract][Full Text] [Related]
20. High molecular weight FGF2 isoforms demonstrate canonical receptor-mediated activity and support human embryonic stem cell self-renewal.
Kole D; Grella A; Dolivo D; Shumaker L; Hermans W; Dominko T
Stem Cell Res; 2017 May; 21():106-116. PubMed ID: 28433654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]